Immunomodulatory drugs (IMiDs) and bortezomib have been recently used in the management of patients with both newly diagnosed and relapsed/refractory multiple myeloma. Except of their direct anti-myeloma effect, these agents also alter the interactions between myeloma cells and marrow microenvironment. Several recent studies have investigated their potential effect on myeloma bone disease. Preclinical studies have demonstrated that IMiDs reduce osteoclast formation and function in vitro. Clinical studies have confirmed that thalidomide reduces markers of bone resorption, while lenalidomide induces osteoclast arrest in myeloma patients. However, IMiDs seem to have no effect on osteoblast exhaustion present in myeloma. The proteasome inhibitor bortezomib restores abnormal bone remodeling through the inhibition of osteoclast function and the increase in osteoblast differentiation and activity in vitro. In myeloma patients, bortezomib reduces biochemical markers of bone resorption and normalizes the RANKL/osteoprotegerin ratio, while at the same time increases bone formation markers reducing levels of dickkopf-1 protein.
Introduction
Multiple myeloma (MM) is a relatively common hematological malignancy characterized by the accumulation of abnormal plasma cells in the bone marrow. Myeloma patients often develop osteolytic bone lesions that result in debilitating skeletal complications such as pathologic fractures, severe bone pain and hypercalcemia. In the absence of effective therapy, more than 50% of patients with Durie-Salmon stage III MM will experience at least one skeletal-related event (SRE) over 2 years. 1 The development of lytic bone lesions is related to an uncoupled bone remodeling: the increased osteoclast-mediated bone resorption is accompanied by a reduction in new bone formation. [2] [3] [4] Bone disease in MM is often assessed by plain radiographs that show radiolucent lesions without calcification, known as 'punched-out' lesions. Although radiographs are useful in diagnosing lytic lesions, they do not provide information about ongoing bone remodeling. Therefore, biochemical markers of bone metabolism have been used in an attempt to assess the rate of bone turnover in patients with MM and to monitor MM bone disease. Bone resorption is mainly assessed by the measurement of serum or urinary degradation products of bone collagen, namely N-and C-terminus cross-linking telopeptide of collagen type-I (NTX, and CTX or ICTP, respectively) and the serum levels of tartrate-resistant acid phosphatase type-5b (TRACP-5b), a molecule which is produced primarily by activated osteoclasts.
On the other hand, bone formation is assessed by the serum measurement of molecules that are produced by osteoblasts, such as the bone-specific alkaline phosphatase (bALP) and osteocalcin (OC). 5 Over the last decade, novel agents have been used in the management of MM. Immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide and proteasome inhibitor, bortezomib, have shown significant anti-myeloma activity in both newly diagnosed and relapsed/refractory MM. [6] [7] [8] Besides their potent efficacy against myeloma cells, these agents modify the interactions between malignant plasma cell and bone marrow microenvironment, and alter abnormal bone metabolism in MM. This review summarizes all available data for the effect of IMiDs, bortezomib and other novel anti-myeloma agents on bone remodeling of MM patients and their possible role in the management of myelomarelated bone disease.
The abnormal coupling between osteoclasts and osteoblasts in myeloma
The adherence of abnormal myeloma cells in the bone marrow stromal cells (BMSCs) leads to the upregulation of a broad spectrum of factors which stimulate osteoclast formation, differentiation and activity, as well as suppression of negative regulators of osteoclastogenesis. These pro-osteoclastogenic cytokines and chemokines include interleukin-6 (IL-6), IL-1a, IL-1b, IL-11, macrophage-colony stimulating factor (M-CSF), tumor necrosis factor-a and -b (TNF-a, -b), macrophage inflammatory proteins-1a and -b (MIP-1a, -b), parathyroid hormone-related peptide and vascular endothelial growth factor. 2, 3, [9] [10] [11] [12] Additional factors including stromal cell-derived factor-1a, IL-3 and hepatocyte growth factor have also been implicated in the regulation of osteoclast formation or activity. [13] [14] [15] These cytokines, which directly or indirectly stimulate osteoclast maturation and increased resorptive activity, can either be produced by MM cells themselves and/or by BMSCs through paracrine/juxtacrine stimulation by MM cells. However, over the last years it has been established that the receptor activator of nuclear factor-kB ligand (RANKL) and osteoprotegerin (OPG) system plays the major role in osteoclastogenesis in MM. Under normal conditions, the RANKL and its decoy receptor, OPG, regulate osteoclast formation, activity and bone resorption. Myeloma cells disrupt the balance between RANKL and OPG by increasing the expression of RANKL and decreasing the expression of OPG in the bone marrow microenvironment; thus leading to increased osteoclast function and bone loss. [16] [17] [18] [19] [20] Moreover, myeloma cells internalize and degrade OPG, thus reducing further its levels in the bone marrow milieu. 21 In addition to increased osteoclast function, MM cells also suppress osteoblast activity through the inhibition of the differentiation of osteoblast precursors and the induction of apoptosis in mature osteoblasts. This osteoblast dysfunction is, at least partially, due to the production of molecules, such as dickkopf-1 (Dkk-1) and soluble frizzle-related protein-2 that antagonize the Wingless-type (Wnt) signaling, a vital pathway for osteoblast differentiation. 4, [22] [23] [24] [25] Furthermore, other molecules including IL-7 and IL-3 have been reported to block osteoblast differentiation, either directly or indirectly, in vitro. 23, 26 Transforming growth factor-b (TGF-b), a potent inhibitor for terminal osteoblast maturation and mineralization, which is abundantly produced and released from bone tissues through enhanced bone resorption, is activated by osteoclastderived acids and metalloproteinases in myeloma lytic lesions contributing to osteoblast dysfunction in MM. [27] [28] [29] In addition to the inhibitory effects on osteoblast differentiation and function, myeloma cells are able to induce apoptosis of osteoblasts by increased expression of Fas ligand and TNF-related apoptosis inducing ligand in myeloma cells and an overexpression of Fas and death receptor-4/5 by osteoblastic lineage cells. 30 Once deregulated by these inhibitory factors, the osteoblast function remains almost permanently ineffective after conventional chemotherapy even in responding patients.
The uncoupling bone remodeling in MM does not have an impact only on the development of bone lytic disease but also on the MM cell growth and survival. For example, IL-6, a potent osteoclast activator, also stimulates the proliferation of malignant plasma cells, and promotes their resistance to drug-induced apoptosis. 31 Recent reports further suggest that osteoclasts promote survival and proliferation of MM plasma cells, 32, 33 while osteoblasts seem to inhibit MM cell growth in the majority of patients. 33 Therefore, the bone microenvironment supports the homing of MM cells, while their ability to further perturb the normal homeostatic regulation of bone remodeling creates a vicious circle in which bone resorption enhances the MM cell compartment with high local levels of growth, promoting and anti-apoptotic cytokines and the MM cells, in return, further deregulate bone remodeling in favor of increased resorption. All these interactions are depicted in Figure 1 .
Bisphosphonates: the cornerstone of the current management of myeloma bone disease
Bisphosphonates are potent inhibitors of osteoclast activity and function, and remain to date the standard practice for the management of MM bone disease. Bisphosphonates inhibit bone resorption by reducing osteoclastic recruitment and maturation, inhibiting the differentiation of monocytes into osteoclasts, inducing osteoclast apoptosis and interrupting their attachment to the bone, as depicted in Figure 2 . 34 In addition to the well-proven anti-resorptive efficacy of bisphosphonates, anti-myeloma activity has also been suggested. 35, 36 Pamidronate is more effective than clodronate, while zoledronic acid is more effective than pamidronate in terms of inducing myeloma cell apoptosis in MM cell lines. 35 Possible mechanisms explaining the anti-myeloma effect of bisphosphonates include the reduction of IL-6 secretion by BMSCs or the expansion of g/d T cells with anti-MM activity. 37 Furthermore, zoledronic acid prolongs survival in myeloma animal models, 36 while pamidronate has either direct or indirect anti-tumor effect in MM patients. 38 Ibandronate reduces the development of osteolytic lesions in murine myeloma models, but no anti-myeloma effect of ibandronate and no reduction in SREs in myeloma patients have been established to date. 39 Oral clodronate, and intravenous pamidronate and zoledronic acid have been found to reduce SREs in randomized clinical trials (Table 1) . [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Nevertheless, zoledronic acid is currently the most commonly used bisphosphonate because it is more potent than pamidronate in reducing bone resorption, it may prolong survival in a subset of MM patients and is very convenient in its administration. 51 However, despite the beneficial effect on SREs, bisphosphonates reduce only osteoclast activity without interfering with osteoblast bone formation.
Side effects of bisphosphonates
Bisphosphonates are, in general, well tolerated in patients with MM. Oral clodronate may cause gastrointestinal side effects including nausea, vomiting or diarrhea. 45 Most commonly reported adverse events with pamidronate and zoledronic acid include skeletal pain, fatigue, nausea, vomiting, flu-like syndrome with fever, mild infusion site reactions, anemia, hypocalcemia and headache; these were similar in frequency between zoledronic acid and pamidronate groups in randomized studies. 52 Uveitis, scleritis and other ocular manifestations have also been reported. 53 Renal impairment has been described in patients with prolonged administration of pamidronate or zoledronic acid. 54 The renal dysfunction is reversible in the majority of patients and re-treatment with the same dose, over a longer infusion time (42 h for pamidronate and 415 min for zoledronic acid), can be safely attempted. In patients with pre-existing renal disease, there is no need for change in dosage or infusion time, provided creatinine clearance is more than 60 ml/min. In general, infusion times less than 2 h for pamidronate or less than 15 min for zoledronic acid should be avoided. 55 
Osteonecrosis of the jaw and bisphosphonates
Avascular osteonecrosis of the jaw (ONJ) is a recent complication that has been described in MM and other cancer patients who have received potent bisphosphonates. 56 ONJ appears to be time dependent, correlates with type of bisphosphonate, older age and dental extractions. [57] [58] [59] No satisfactory therapy is currently available, while surgical therapy may help only a subset of myeloma patients with ONJ. 60 Therefore, patients who receive bisphosphonates should improve their oral hygiene, while oncologists and dentists should be aware of this complication and its management. Reinitiating bisphosphonate therapy in patients suffering osteonecrosis is debated and warrants further study. Pathogenesis of ONJ remains unclear and experimental models are urgently needed to clarify its mechanisms.
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What is the optimal duration of bisphosphonates in myeloma patients?
This question has not been answered to date because this issue has not been the subject of any clinical trial. The ASCO guidelines suggest that bisphosphonates should be administered 'until there is evidence of a substantial decline in the patient's general performance status'; 55 this could result in the administration of bisphosphonates for several years in some patients. Nevertheless, the study, which current guidelines were based on, administered pamidronate for only 21 cycles, while the longest duration of bisphosphonate treatment in other large studies has been 2 years. According to all available data, Mayo Clinic experts recommend discontinuation of bisphosphonates after 2 years of therapy for patients who achieve complete response (CR) and/or plateau phase, while patients whose disease is active, who have not achieved a response or who have threatening bone disease beyond 2 years, may continue on bisphosphonates every 3 months. 61 In accordance with these suggestions the International Myeloma Working Group (IMWG) has recently suggested that bisphosphonate therapy is not recommended beyond the first year in patients who have achieved a CR or a very good partial response (vgPR) with transplantation and/or a novel therapy combination and have no active bone disease. For patients achieving less than a vgPR and/ or those with ongoing active bone disease, further bisphosphonate use has been recommended. After 2 years, patients without active bone disease can discontinue bisphosphonate use, while patients with continued active bone disease after 2 years of bisphosphonate therapy can continue on bisphosphonates at the discretion of the primary physician. In patients who experience relapse with new bone disease, bisphosphonate therapy should be reinstituted. Pamidronate or clodronate is preferred for longer term use (42 years), according to IMWG. 62 Physicians should emphasize to their patients the need to avoid These cytokines include IL-6, IL-11, IL-1b, M-CSF that are mainly produced by BMSCs and MIP-1a, MIP-1b, stromal cell-derived factor-1a, IL-3, HGF, OPN that are mainly produced by myeloma cells. The most potent activator of osteoclasts is the RANKL, which is over-produced in the bone marrow milieu of MM. Furthermore, OPG, the decoy receptor of RANKL is produced in lower amounts by BMSCs in the myeloma marrow microenvironment, while myeloma cells internalize and degrade OPG through CD138 (sydecan-1). Thus the ratio of RANKL/OPG is in favor of RANKL, which leads to increased osteoclastogenesis and osteoclast function. Mature osteoclasts resorb the bone collagen and produce degradation products of collagen type-I that can be measured in the urine or the serum of the patients (NTX, CTX, ICTP). They also produce TRACP-5b while destroying the bone. Further to osteoclast activation, myeloma cells produce molecules that can inhibit osteoblast differentiation and function, such as Dkk-1 and sFRP-2; thus osteoblasts are functionally exhausted in MM. The vicious cycle is completed by the survival benefit of myeloma cells due to osteoclast activation (through increased IL-6 production or through other not identified mechanism). BMSCs, bone marrow stromal cells; IL-6, interleukin-6; M-CSF, macrophage-colony stimulating factor; MIP-1a, macrophage inflammatory protein-1a; MIP-1b, macrophage inflammatory protein-1b; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-kB ligand.
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A recent retrospective analysis in 106 MM patients showed that there was no difference in terms of SREs between patients who received bisphosphonates monthly until tolerated (group A) and patients who received bisphosphonates monthly during the first year and then every 3 months (group B). ONJ occurred in six patients of group A and one of group B (P ¼ 0.049); the risk of ONJ was eight-fold lower with the reduced schedule than with the standard schedule of bisphosphonate administration. However, randomized trials focused on the duration of bisphosphonates administration are urgently needed to clarify this issue. The time of initiating treatment with bisphosphonates is also controversial. All patients with MM who have lytic lesions need to start bisphosphonates therapy. The ASCO guidelines have suggested that myeloma patients with osteopenia alone may be treated with bisphosphonates, but there is no such recommendation for patients with solitary plasmacytoma or smoldering myeloma without documented lytic bone disease. 55 Due to the side effects of bisphosphonates, novel agents that efficiently alter abnormal bone remodeling in myeloma are under thorough investigation.
Immunomodulatory agents and myeloma bone disease

Preclinical studies
Thalidomide and other IMiDs, such as CC-4047 (Actimid) and lenalidomide, are very effective for the management of patients with MM. 6, 7, [64] [65] [66] The first evidence of the effect of IMiDs on bone metabolism came from the work of Anderson et al. 67 who found that thalidomide and mainly CC-4047 almost completely abrogated RANKL-induced osteoclast formation by downregulation of the expression of PU.1, which is a major transcriptional factor for osteoclastogenesis. CC-4047 inhibited the formation of mature multinucleated osteoclasts, while it induced the production of an overgrowing population of small cells that lacked the features and activity of osteoclasts. CC-4047 acted especially at the early stages of the osteoclast differentiation. In that study, significant inhibition of osteoclast formation was observed at concentrations of 1 mM of CC-4047, which is similar or even lower than that achieved in vivo after the therapeutic administration of this agent. Thalidomide exhibited similar but less potent effects than CC-4047, suggesting that thalidomide is less potent than CC-4047, at least in the inhibition of osteoclast formation. 67 Lenalidomide also inhibited osteoclast formation through similar mechanisms, such as the downregulation of PU.1 gene expression. In a recent study, lenalidomide inhibited osteoclast differentiation in a dose-dependent manner. The median percentage of osteoclast counts identified by flow cytometric analysis, using the anti-a V b 3 integrin antibody, was 71% without lenalidomide. This was reduced to 63% when 2 mM of lenalidomide were added in the culture system and 45% when 10 mM of lenalidomide were added in the culture system. Lenalidomide also reduced the TRAP ( þ ) osteoclasts and subsequent bone resorption, as assessed by the reduction of soluble collagen I fragments collected from the supernatant of the cultures. However, lenalidomide did not alter the counts of mature osteoclasts, but strongly inhibited B-cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) that are major MM growth and survival factors and are produced mainly by osteoclasts. 68 These studies suggest that IMiDs through the inhibition of the proliferation of myeloma 69 and other malignant B-cells 70 and the reduction of osteoclast formation seem to break the vicious cycle between myeloma cells and osteoclasts, leading to further reduction of tumor burden and bone resorption. However, despite the inhibitory effect on osteoclast, no effect on osteoblast activity and bone formation was observed with IMiDs in the preclinical setting. All these interactions are depicted in Figure 2 .
Clinical studies
Two clinical, phase II, trials have studied the effect of thalidomide on bone metabolism of patients with MM (Table 2 ). In the first study, Terpos et al. 71 showed that thalidomide in dexamethasone produced a significant reduction of both studied serum markers of bone resorption, that is CTX and TRACP-5b at the 3rd month after initiation of treatment, which continued at the 6th month of the study. The combined treatment also reduced sRANKL levels and sRANKL/OPG ratio at 6 months after treatment initiation. Furthermore, there was a strong correlation between changes of sRANKL/OPG ratio and changes of TRACP-5b and CTX, suggesting that the reduction of bone resorption by thalidomide is, at least partially, due to the reduction of RANKL levels. 71 This result is also supported by the finding of Anderson et al. 67 that thalidomide can abrogate RANKL-induced osteoclast formation. Despite the reduction of bone resorption, intermediate doses of thalidomide and dexamethasone showed no effect on bone formation, as assessed by serum levels of bALP and OC. Thus this treatment produced no healing of the observed lytic lesions after radiographic evaluation of responders at 6 months after treatment, though only one of four patients who progressed while on treatment presented with new lytic lesions at the time of progression. 71 In the second study, Tosi et al. 72 showed that thalidomide can reduce bone resorption in newly diagnosed MM patients too. In this study, 40 patients received the combination of thalidomide (100 mg/day for 2 weeks and then 200 mg/day), dexamethasone (40 mg/day on days 1-4, 9-12, 17-20/28 on odd cycles and on days 1-4 on even cycles) and zoledronic acid (4 mg/28 days) for 4 months. The OR rate was 77.5%. A significant reduction in both studied markers of bone resorption, that is urinary NTX and serum CTX, was observed, but only in responders. This reduction was accompanied by a reduction in bone pain in 60% of the patients. However, markers of bone formation (bALP and OC) were also reduced in all patients (responders and refractory), suggesting that the combined regimen may have a negative effect on the already exhausted osteoblasts of newly diagnosed patients, possibly due to the concomitant use of dexamethasone. 72 There are no published clinical data for the role of CC-4047 and lenalidomide in bone metabolism of MM. The only available information comes from an abstract that was presented at ASH 2006, where lenalidomide inhibited osteoclast differentiation and subsequent bone resorption in 11 MM patients. 68 In conclusion, it seems that thalidomide and IMiDs reduce bone resorption either directly through the inhibition of osteoclast formation or indirectly through the reduction of tumor burden and therefore they have a beneficial effect on altered bone remodeling in MM. For IMiDs, this has to be confirmed by further clinical studies. However, these agents seem to have no effect on osteoblast function and bone formation.
Bortezomib and myeloma bone disease
Preclinical studies
Bortezomib is a first-in-class proteasome inhibitor with known activity against myeloma cells 73 and has been licensed for the treatment of MM patients. 8, 74, 75 Bortezomib affects osteoclast differentiation and function in a dose-dependent manner, thus reducing subsequent bone resorption. [76] [77] [78] Bortezomib seems to act in both early and late phase of osteoclast differentiation, through the inhibition of p38 mitogen-activated protein kinase pathways (early phase), activator protein-1 and nuclear factorkB (NF-kB) signaling (late phase). [77] [78] [79] The concentrations of bortezomib used in these studies were typically less than that required to induce tumor cell apoptosis. Bortezomib also inhibited the secretion of BAFF and APRIL by osteoclasts. 68 These data suggest that bortezomib inhibits osteoclast activity and thus it may interfere in the vicious cycle between myeloma cells and osteoclasts.
However, the major interest for the effect of bortezomib on bone metabolism in MM has been created by the observation that bortezomib stimulates osteoblast function. The stimulation of new bone formation was firstly reported by Oyajobi et al.
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Ubiquitin-proteasome pathway was known to regulate osteoblast differentiation, 80 and Garrett et al. 81 had demonstrated that proteasome inhibitors stimulate bone formation in neonatal murine calvarial bones and in vivo in mice. Bortezomib was shown to induce osteoblast differentiation and increase the size of osteoblastic colony forming units. 82, 83 Furthermore, Giuliani et al. 83 have just published that bortezomib significantly increased the transcription factor Runx2/Cbfa1 activity in human osteoblast progenitors and mature osteoblasts, without affecting nuclear and cytoplasmatic active b-catenin levels. The stimulatory effect of bortezomib on Runx2/Cbfa1 activity was observed at low concentrations of the drug (2 nM), whereas higher doses did not show any effect. This behavior was not related to a toxic effect of bortezomib as the authors found that bortezomib did not induce apoptosis or inhibit proliferation of both osteoblast progenitors and mature osteoblasts at concentration ranging between 2 and 5 nM. Moreover, in the SCID-rab model of myeloma, bortezomib increased bone mineral density (BMD) in responding mice and was associated with increased numbers of OC-expressing osteoblasts and reduced numbers of TRACP-expressing osteoclasts. 77 Separating the direct effect of bortezomib on osteoblast differentiation and indirect effects via the inhibition of tumor growth in vivo is difficult (Figure 2 ). However, it does highlight the potential interaction between myeloma growth and osteoblasts, which seems to be crucial for myeloma cell survival. 33 
Clinical studies
An increasing number of studies are reporting the effects of bortezomib on bone formation in the clinical setting, confirming preclinical observations. The first indications that bortezomib may have a positive effect on bone formation came from Zangari et al., 84, 85 who observed a significant increase in serum ALP levels in patients who responded to treatment with bortezomib. Similarly Shimazaki et al. 86 showed in a patient with refractory MM, who was treated with the combination of bortezomib and dexamethasone, that response to treatment was accompanied by increases in both serum total ALP and bALP.
Osteoblast stimulation by bortezomib was also reported by Heider et al., 87 who measured changes in bALP and OC, in patients who received bortezomib7dexamethasone (n ¼ 25) and in a control group of patients who received adriamycin/ dexamethasone, melphalan/prednisone or thalidomide-containing therapy (n ¼ 58). Significant increases in bALP and OC following bortezomib treatment were observed in both responders and non-responders, irrespective of whether dexamethasone was included in the treatment regimen. Conversely, in the control group of patients who did not receive bortezomib, no increase in osteoblast markers was seen, suggesting that the effect on osteoblasts is unique to the proteasome inhibitor. These results are in accordance with those by Giuliani et al., 83 who found significant increases in the number of osteoblasts/ mm 2 of bone tissue and Runx2/Cbfa1-positive osteoblasts in the trephine biopsies of responding patients to bortezomib, but not in those who did not respond. Furthermore, Terpos et al. 88 investigated the effect of bortezomib on bone turnover in patients (n ¼ 34) with relapsed MM. Patients received bortezomib 1.3 mg/m 2 on days 1, 4, 8 and 11 of a 3-week cycle for four cycles. Responders could continue bortezomib for four more cycles and non-responders could receive dexamethasone in addition to bortezomib. After four cycles of treatment, the OR rate was 66% (8% CR and 58% PR). Bortezomib administration resulted in a significant reduction in Dkk-1 and RANKL levels, with concomitant reduction in osteoclast function and bone resorption, as assessed by TRACP-5b and CTX serum levels, respectively. The reduction in osteoclast function and bone resorption occurred irrespective of response to therapy. In addition, bortezomib significantly increased levels of bALP and OC (Table 2) . CR or vgPR patients had greater elevations of bALP levels. Interestingly, 75% of non-responders had an increase in bALP levels following four cycles of bortezomib treatment. Although no healing of lytic bone lesions was observed, even in patients who achieved a CR, longer followup or prolonged bortezomib therapy may be needed to demonstrate a radiographic improvement after increased bone formation. 88 However, when bortezomib is combined with other anti-myeloma agents, such as melphalan, dexamethasone and intermittent thalidomide (VMDT regimen), the reduction of Dkk-1, sRANKL, sRANKL/OPG ratio, MIP-1a and CTX was not accompanied by an increase in bALP and OC. This observation may suggest that bortezomib in combination with other antimyeloma agents may lose its beneficial effect on osteoblasts. 89 Indeed, Heider et al. 87 found a lower increase in bALP in patients who received the combination of bortezomib with dexamethasone compared with patients who received bortezomib alone.
The reduction of bone resorption (assessed by CTX or NTX levels) after bortezomib has been confirmed by other recent studies as well. 83, 90 The effect on osteoclastic bone resorption was seen even in the absence of an effect on malignant plasma cells. 90 At this point, it is crucial to mention that different effective anti-myeloma regimens in combination with bisphosphonates also reduce bone resorption through the reduction of tumor burden and the inhibition of osteoclast function. [91] [92] [93] It is very difficult to distinguish in the previously mentioned clinical studies whether the reduction of bone resorption is due to a direct effect of bortezomib on osteoclast, to an indirect effect through reduction of tumor burden or to both. Thus, randomized trials are needed to explore whether bortezomib alone or in combination with other agents, including bisphosphonates, can inhibit bone resorption more effectively.
Effect of other novel anti-myeloma agents on bone metabolism
Recent studies, published mainly in abstract forms, suggest that several novel agents with anti-myeloma activity have also an impact on bone metabolism in MM. Most of these agents inhibit osteoclast formation.
SDX-308 is a novel and potent etodolac structural analog with demonstrated cytotoxicity against MM cells, which induced potent inhibition (60-80%) of osteoclast development in MM patients. SDX-308 also inhibited osteoclast formation in vitro through the reduction of constitutive and RANKL-stimulated NF-kB activation and the inhibition of phosphorylation of p65, IkBa and p65 nuclear translocation.
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AZD6244 is another anti-myeloma agent, which blocks the extracellular signal-regulated kinase 1/2 (ERK1/2) MAP kinase pathway and is very active in myeloma cell lines. In a recent report, AZD6244 inhibited osteoclast differentiation induced by M-CSF and RANKL and reduced subsequent bone resorption in a dose-dependent manner. Furthermore, AZD6244 downregulated MIP-1a, BAFF and APRIL secretion by osteoclasts, phenomenon that could contribute to the MM cell apoptosis in the marrow microenvironment.
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KD5170 is a histone deacetylase (HDAC) inhibitor which has been shown in vitro to inhibit not only osteoclast formation but also the proliferation of MM cells, possibly interfering into the vicious cycle between MM cells and osteoclast. 96 It is already known that HDAC inhibitors, such as trichostatin A, sodium butyrate and FR901228, can block osteoclastogenesis. 97, 98 Recently, another HDAC inhibitor, PXD 101, was also shown to inhibit osteoclast formation synergistically with bortezomib. 99 Finally, other proteasome inhibitors, such as MG-132 and MG-262, reduce both osteoclast differentiation and activity of mature osteoclasts in vitro; 78, 100 and others, such as epoxomicin, PS-1 and lactacystin, induce osteoblast function and bone formation. 81 An interesting agent that seems to also restore osteoblast function is SB431542, an inhibitor of TGF-b type I receptor kinase. This agent antagonized the inhibitory effects of conditioned media from MM cell lines (RPMI8226 and U266) and bone marrow plasma from patients with MM, enhancing the BMP-induced mineralized nodule formation. In addition, the induction of osteoblast maturation caused by SB431542 downregulated the production of IL-6 and upregulated the production of OPG leading to osteoclast inhibition. Therefore, SB431542, through the blockade of TGF-b actions, releases osteoblasts from the differentiation arrest in MM bone disease, while concomitantly suppresses osteoclastogenesis to ameliorate bone destruction and at the same time suppressing MM expansion by disrupting the MM niche. 29 
Conclusion
Novel anti-myeloma agents, such as IMiDs, bortezomib and more recent ones, alter abnormal bone metabolism in myeloma patients. Most of them reduce bone resorption either directly through the inhibition of osteoclast formation or indirectly through the modification of interactions between malignant plasma cells and osteoclasts. In terms of the restoration of osteoblast function, based on available evidence, we can suppose that bortezomib may directly stimulate osteoblast differentiation. However, to date, evidence of the effect of bortezomib on clinical end points specific to bone, such as SREs and BMD, is limited, possibly as a result of relatively short follow-up periods. It is therefore important to design prospective trials that investigate end points related to bone formation, the results of which will be eagerly anticipated. It would be also of great interest to see the results of studies using combination regimens including novel agents with or without the presence of bisphosphonates. In this period of skepticism about the prolonged use of bisphosphonates due to side effects, the administration of agents, such as bortezomib, that alter bone metabolism by both reducing bone resorption and enhancing bone formation may alter our way of management myeloma bone disease in the near future. However, more data with clinical end points are needed before making specific recommendations.
